Research Topics
Genomes and Genes | gallium radioisotopesSummarySummary: Unstable isotopes of gallium that decay or disintegrate emitting radiation. Ga atoms with atomic weights 63-68, 70 and 72-76 are radioactive gallium isotopes. Top Publications
|
More Information
Publications
- Petrik M, Haas H, Schrettl M, Helbok A, Blatzer M, Decristoforo C. In vitro and in vivo evaluation of selected 68Ga-siderophores for infection imaging. Nucl Med Biol. 2012;39:361-9 pubmed publisher..We report here on the in vitro and in vivo evaluation of other siderophores radiolabelled with (68)Ga as potential radiopharmaceuticals for infection imaging...
- Afshar Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart H, Hadaschik B, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-95 pubmed publisher..Within healthy organs, kidneys and salivary glands demonstrated the highest radiotracer uptake. Lesions suspicious for PC presented with excellent contrast as early as 1 h p.i. with high detection rates even at low PSA levels. ..
- Altai M, Strand J, Rosik D, Selvaraju R, Eriksson Karlström A, Orlova A, et al. Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ??Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA. Bioconjug Chem. 2013;24:1102-9 pubmed publisher..In conclusion, influence of chelators on biodistribution of Affibody molecules depends on the radionuclides and reoptimization of labeling chemistry is required when a radionuclide label is changed...
- Al Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, et al. Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res. 2007;27:4087-94 pubmed
- Jeong J, Hong M, Chang Y, Lee Y, Kim Y, Cheon G, et al. Preparation of a promising angiogenesis PET imaging agent: 68Ga-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med. 2008;49:830-6 pubmed publisher..The labeled RGD so produced was subjected to an in vitro binding assay and in vivo biodistribution and PET studies...
- Fani M, André J, Maecke H. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging. 2008;3:67-77 pubmed publisher..Kit-formulated precursors along with the generator may be provided, similar to the (99)Mo/(99m)Tc-based radiopharmacy, still the mainstay of nuclear medicine...
- Haug A, Auernhammer C, Wängler B, Tiling R, Schmidt G, Goke B, et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2009;36:765-70 pubmed publisher..To compare the diagnostic impact of (68)Ga-DOTA-TATE and (18)F-DOPA PET in the diagnosis of well-differentiated metastatic neuroendocrine tumours (NET)...
- Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging. 2010;54:68-75 pubmed..This study reports our initial experiences with these two PET modalities on initial diagnosis, staging and restaging in NET patients...
- Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51:669-73 pubmed publisher..The aim of this study was to assess the impact of (68)Ga-DOTANOC PET/CT on the clinical management of NET patients...
- Virgolini I, Ambrosini V, Bomanji J, Baum R, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004-10 pubmed publisher..The same has been done with the relevant and recent literature in this field and the final result has been discussed by distinguished experts...
- Jindal T, Kumar A, Venkitaraman B, Meena M, Kumar R, Malhotra A, et al. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids. Cancer Imaging. 2011;11:70-5 pubmed publisher..001) in typical carcinoids compared with atypical carcinoids. The different uptake patterns on [18F]FDG and [68Ga]DOTATOC-PET/CT. and the ratio of SUVmax may be helpful in differentiating between typical and atypical carcinoids...
- Kramer Marek G, Shenoy N, Seidel J, Griffiths G, Choyke P, Capala J. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging. 2011;38:1967-76 pubmed publisher..Therefore, there is a need for a new means to assess HER2/neu expression in vivo. In this work, we used (68)Ga-labeled DOTA-Z(HER2:2891)-Affibody to monitor HER2/neu expression in a panel of breast cancer xenografts...
- Treglia G, Castaldi P, Villani M, Perotti G, de Waure C, Filice A, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:569-80 pubmed publisher..To retrospectively evaluate and compare (18)F-FDG, (18)F-DOPA and (68)Ga-somatostatin analogues for PET/CT in patients with residual/recurrent medullary thyroid carcinoma (MTC) suspected on the basis of elevated serum calcitonin levels...
- Fournier P, Dumulon Perreault V, Ait Mohand S, Tremblay S, Benard F, Lecomte R, et al. Novel radiolabeled peptides for breast and prostate tumor PET imaging: (64)Cu/and (68)Ga/NOTA-PEG-[D-Tyr(6),?Ala(11),Thi(13),Nle(14)]BBN(6-14). Bioconjug Chem. 2012;23:1687-93 pubmed publisher..Considering their good imaging characteristics, both (64)Cu/NOTA-PEG-BBN(6-14) and (68)Ga/NOTA-PEG-BBN(6-14) are promising candidates for GRPR-targeted PET imaging of breast and prostate cancers...
- Honarvar H, Jokilaakso N, Andersson K, Malmberg J, Rosik D, Orlova A, et al. Evaluation of backbone-cyclized HER2-binding 2-helix affibody molecule for in vivo molecular imaging. Nucl Med Biol. 2013;40:378-86 pubmed publisher..The goal of this study was to develop a novel 2-helix Affibody molecule based on backbone cyclization by native chemical ligation (NCL)...
- Li Z, Chen K, Chen X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging. 2008;35:1100-8 pubmed publisher..The goal of this study was to investigate the feasibility of (68)Ga-labeled RGD peptides for tumor imaging...
- Kwekkeboom D, Kam B, van Essen M, Teunissen J, van Eijck C, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53-73 pubmed publisher..If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable GEPNETs...
- Pałyga I, Kowalska A, Gąsior Perczak D, Tarnawska Pierścińska M, Słuszniak J, Sygut J, et al. The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (??Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Endokrynol Pol. 2010;61:507-11 pubmed..Two patients with positive diagnostic imaging tests were referred for surgery including resection of cervical lymph nodes with histopathological examination for assessment of metastases...
- Frilling A, Sotiropoulos G, Radtke A, Malago M, Bockisch A, Kuehl H, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252:850-6 pubmed publisher..To evaluate the impact of 68Ga-DOTATOC positron emission tomography (PET)/computed tomography (CT) on the multimodal management of neuroendocrine tumors (NET)...
- Petrik M, Haas H, Dobrozemsky G, Lass Florl C, Helbok A, Blatzer M, et al. 68Ga-siderophores for PET imaging of invasive pulmonary aspergillosis: proof of principle. J Nucl Med. 2010;51:639-45 pubmed publisher..fumigatus virulence. We aimed to evaluate the potential of siderophores radiolabeled with (68)Ga, a positron emitter with complexing properties comparable to those of Fe(III), as a radiopharmaceutical for imaging IPA...
- Khan M, Khan S, El Refaie S, Win Z, Rubello D, Al Nahhas A. Clinical indications for Gallium-68 positron emission tomography imaging. Eur J Surg Oncol. 2009;35:561-7 pubmed publisher..The advantage of in-house preparation of (68)Ga without necessity of a cyclotron, and the new generator configuration with future possibility of freeze-dried kits would make it a promising PET agent for the future...
- Eder M, Schafer M, Bauder Wüst U, Hull W, Wängler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688-97 pubmed publisher..It could be demonstrated that the PET-imaging property of a urea-based PSMA inhibitor could significantly be improved with HBED-CC. ..
- Riss P, Kroll C, Nagel V, Rösch F. NODAPA-OH and NODAPA-(NCS)n: synthesis, 68Ga-radiolabelling and in vitro characterisation of novel versatile bifunctional chelators for molecular imaging. Bioorg Med Chem Lett. 2008;18:5364-7 pubmed publisher..Protein binding and exemplified conjugation are also reported...
- Davies N, Suryo Rahmanto Y, Chitambar C, Richardson D. Resistance to the antineoplastic agent gallium nitrate results in marked alterations in intracellular iron and gallium trafficking: identification of novel intermediates. J Pharmacol Exp Ther. 2006;317:153-62 pubmed..In contrast to the general view that (67)Ga and (59)Fe use the same or similar uptake pathways, we show that their distribution and trafficking is markedly different in R and S cells...
- Skouri H, Dec G, Friedrich M, Cooper L. Noninvasive imaging in myocarditis. J Am Coll Cardiol. 2006;48:2085-93 pubmed..Novel imaging modalities that are currently in preclinical development are discussed with recommendations for future clinical research...
- Lendvai G, Velikyan I, Bergstrom M, Estrada S, Laryea D, Välilä M, et al. Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats. Eur J Pharm Sci. 2005;26:26-38 pubmed..This study supplies a base for the further development of 68Ga-labelled oligonucleotides as pharmacokinetic tools and a potential future use for in vivo imaging of gene expression...
- Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker D, Doll J, et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med. 2001;42:1053-6 pubmed..Because of PET's increased spatial resolution and its ability to absolutely quantify biodistribution, a PET tracer for SSTR imaging would be desirable...
- Meyer G, Mäcke H, Schuhmacher J, Knapp W, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging. 2004;31:1097-104 pubmed..The system was set up and operated in a "hot lab" by personnel with no previous experience in the preparation of PET radiopharmaceuticals...
- Maecke H, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46 Suppl 1:172S-8S pubmed..In addition, (68)Ga-DOTA-based bombesin derivatives are being investigated with some success in patients with prostate cancer...
- Boerman O, Dams E, Oyen W, Corstens F, Storm G. Radiopharmaceuticals for scintigraphic imaging of infection and inflammation. Inflamm Res. 2001;50:55-64 pubmed..Here, the characteristics and the diagnostic potential of established and experimental radiopharmaceuticals for infection and inflammation imaging are reviewed...
- Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-18 pubmed..PET was compared with conventional scintigraphy and dedicated CT...
- Mathias C, Lewis M, Reichert D, Laforest R, Sharp T, Lewis J, et al. Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nucl Med Biol. 2003;30:725-31 pubmed..The autoradiographic images of 1 mm tumor sections demonstrate the gross heterogeneity of the KB cell tumor xenograft, as well as subtle disparity in the regional accumulation of the two radiotracers...
- Hoffend J, Mier W, Schuhmacher J, Schmidt K, Dimitrakopoulou Strauss A, Strauss L, et al. Gallium-68-DOTA-albumin as a PET blood-pool marker: experimental evaluation in vivo. Nucl Med Biol. 2005;32:287-92 pubmed..Our findings support clinical imaging using 68Ga-DOTA-labeled human serum albumin (HSA). The generator-produced label makes 68Ga-DOTA-labeled albumin continuously available even to centers lacking an in-house cyclotron...
- Roivainen A, Tolvanen T, Salomäki S, Lendvai G, Velikyan I, Numminen P, et al. 68Ga-labeled oligonucleotides for in vivo imaging with PET. J Nucl Med. 2004;45:347-55 pubmed..The biologic evaluation in living rats of (68)Ga-labeled oligonucleotides as imaging agents for PET is reported...
- Ishizaka A, Hasegawa N, Nakamura K, Takagi Y, Takano M, Yamaguchi K, et al. Usefulness of pulmonary vascular leakiness assessment in interstitial pneumonitis. Chest. 2001;119:1455-60 pubmed
- Velikyan I, Beyer G, Langstrom B. Microwave-supported preparation of (68)Ga bioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15:554-60 pubmed..The first automated prototype using this technology is being tested...
- Wild D, Mäcke H, Waser B, Reubi J, Ginj M, Rasch H, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724 pubmed
- Breeman W, de Jong M, De Blois E, Bernard B, Konijnenberg M, Krenning E. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging. 2005;32:478-85 pubmed..Here we present the practical aspects and the results of radiolabelling DOTA-peptides with a TiO2-based commercially available 68Ge/68Ga generator...
- Henze M, Dimitrakopoulou Strauss A, Milker Zabel S, Schuhmacher J, Strauss L, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46:763-9 pubmed..In contrast to (18)F-FDG, this ligand shows high meningioma-to-background ratios. The aim was to evaluate kinetic parameters in meningiomas before radiotherapy...
- Govindan S, Michel R, Griffiths G, Goldenberg D, Mattes M. Deferoxamine as a chelator for 67Ga in the preparation of antibody conjugates. Nucl Med Biol. 2005;32:513-9 pubmed..In conclusion, DFO does not seem to be a suitable chelator for (67)Ga conjugation for our purposes...
- Bar Shalom R, Yefremov N, Guralnik L, Keidar Z, Engel A, Nitecki S, et al. SPECT/CT using 67Ga and 111In-labeled leukocyte scintigraphy for diagnosis of infection. J Nucl Med. 2006;47:587-94 pubmed..The present study evaluated the role of SPECT/CT as an adjunct to (67)Ga (GS) or (111)In-labeled white blood cell (WBC) scintigraphy for diagnosis or localization of infection...
- Sharma V, Prior J, Belinsky M, Kruh G, Piwnica Worms D. Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med. 2005;46:354-64 pubmed
- Eisenwiener K, Prata M, Buschmann I, Zhang H, Santos A, Wenger S, et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem. 2002;13:530-41 pubmed..The results indicate an improved biological behavior which is likely due to the fact that an additional spacer group separates the chelate from the pharmacophoric part of the somatostatin analogue...
- Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751-7 pubmed..It is concluded that PET using (68)Ga-DOTATOC results in high tumour to non-tumour contrast and low kidney accumulation and yields higher detection rates as compared with (111)In-octreotide scintigraphy...
- Ando A, Nitta K, Ando I, Sanada S, Katsuda S, Tonami N, et al. Mechanism of gallium 67 accumulation in inflammatory tissue. Eur J Nucl Med. 1990;17:21-7 pubmed
- Antunes P, Ginj M, Zhang H, Waser B, Baum R, Reubi J, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?. Eur J Nucl Med Mol Imaging. 2007;34:982-93 pubmed..In preclinical studies it has shown a striking superiority over its 111In-labelled congener. The purpose of this study was to evaluate whether third-generation somatostatin-based, radiogallium-labelled peptides show the same superiority...
- Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi J, et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2007;34:1198-208 pubmed
- Salloum E, Brandt D, Caride V, Cornelius E, Zelterman D, Schubert W, et al. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. J Clin Oncol. 1997;15:518-27 pubmed..To evaluate the utility of periodic gallium (67Ga) scans in the management of patients with Hodgkin's disease...
- Hsiao Y, Mathias C, Wey S, Fanwick P, Green M. Synthesis and biodistribution of lipophilic and monocationic gallium radiopharmaceuticals derived from N,N'-bis(3-aminopropyl)-N,N'-dimethylethylenediamine: potential agents for PET myocardial imaging with 68Ga. Nucl Med Biol. 2009;36:39-45 pubmed publisher